Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy

This first-in-human trial is investigating use of a fourth-generation CAR T-cell product containing both humanized anti-CD19 CAR and IL-18 for patients with relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia. At the time of the reporting, seven patients were evaluable for response, with the overall response rate at M3 of 100% (complete response 57%, partial response 43%). All patients were alive at a mean follow up of 8 months, and none of the patients who experienced a complete response had disease progression by the time of reporting.